

## Knowledge Check **2**

**1**

How is biomarker testing utilized in precision oncology?

- a Diagnosis purposes
- b Treating cancers
- c Aiding prognosis
- d All of the above

**2**

A good biomarker test should have which of the following characteristics? **Select all that apply:**

- a Actionable, prognostic and/or predictive
- b Sufficient sensitivity, specificity, accuracy, and precision to detect actionable biomarkers
- c Tightly controlled specimen collection, handling, and processing
- d Highly regulated process to returning results to inform clinical decisions

**3**

Which statement(s) best describes clinical utility?

- a Accurately and reliably measures the presence or absence of a biomarker
- b Accurately and reliably identifies a biologically defined disorder
- c Evidence to support the use of a biomarker that can guide clinical decisions
- d B & C
- e All of the above

**4**

Which testing method(s) can reliably detect fusions? **Select all that apply:**

- a IHC
- b FISH
- c RT-PCR
- d RNA-based NGS
- e DNA-based NGS

**5**

Which of these statements are true about reflex testing?

- a Can reduce turnaround time
- b Can be integrated into patients EHR
- c Tests are automatically added in specific situations
- d All of the above

# ANSWERS

**1** D. Precision oncology uses molecular biomarkers to aid in the diagnosis, prognosis, or treatment of cancer.<sup>1</sup>


**2** A, B, and C. According to clinical guidelines and expert opinions, the 7 characteristics of a good biomarker test are as follows:

- It is actionable, prognostic, and/or predictive<sup>2,3</sup>
- It is supported by the highest level of evidence<sup>2</sup>
- It provides reproducible results (>95%)<sup>4,5</sup>
- It possesses sufficient sensitivity, specificity, accuracy, and precision (<1% to 5% LOD) to detect actionable biomarkers<sup>2-5</sup>
- It has tightly controlled specimen collection, handling, and processing<sup>2</sup>
- It delivers timely results which impact treatment decisions<sup>6-8</sup>
- It has predetermined cutoff points/categories<sup>2</sup>

**3** C. Clinical utility is when a biomarker test has high levels of evidence that use of the biomarker can result in guiding clinical decisions that result in improved clinical outcomes compared with those if the biomarker test results were not applied.<sup>9</sup>

**4** B, C, & D. Gene rearrangements can be reliably detected by FISH, RT-PCR (known rearrangements) and RNA-based NGS. Some, but not all, DNA-based NGS assays can detect fusions, as the enrichment strategy will impact the ability to detect fusions in these assays. IHC assesses protein expression; therefore, it cannot differentiate between protein overexpression and a bona fide fusion event.<sup>1</sup>

**5** D. Reflex testing is the automatic addition of tests in the SOPs by pathologists, and it may be integrated into the electronic health record. Studies suggest reflex testing may reduce the turnaround times for molecular testing results.<sup>10-13</sup>



This knowledge check is connected to the chapter “The Growing Role for Molecular Diagnostics in Cancer Care.” To get a copy of this and other chapters, please visit: <https://www.hcp.novartis.com/precision-medicine>



**Looking to speak to a Precision Medicine Liaison?**  
**Scan this QR code**  
<https://hcp.novartis.com/precision-medicine/contact-us>

The content provided herein is for your background and educational purposes only. The material is for your sole use and may not be altered or further disseminated in any fashion for further use.

DNA, deoxyribonucleic acid; FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; LOD, limit of detection; NGS, next-generation sequencing; RNA, ribonucleic acid; RT-PCR, real time-polymerase chain reaction; SOPs, standard operating procedures.

**References:** 1. Chakravarty D et al. *J Clin Oncol*. 2022;40(11):1231-1258. 2. Hayes DF. *J Clin Oncol*. 2021;39(3):238-248. 3. Vidwans SJ et al. *Oncoscience*. 2014;1(10):614-623. 4. Pepe MS et al. *J Natl Cancer Inst*. 2001;93(14):1054-1061. 5. Jennings LJ et al. *J Mol Diagn*. 2017;19(3):341-365. 6. European Society for Medical Oncology. <https://oncologypro.esmo.org/education-library/factsheets-on-biomarkers/multigene-sequencing-in-breast-cancer#page>. Accessed April 26, 2022. 7. Veljovic M et al. ASCO 2015. Abstract e17698. 8. Lim C et al. *Ann Oncol*. 2015;26(7):1415-1421. 9. Hayes DF. *Mol Oncol*. 2015;9(5):960-966. 10. Murphy MJ. *Ann Clin Biochem*. 2021;58(2):75-77. 11. Lau-Min KS et al. *JCO Precis Oncol*. 2021;5:PO.20.00418. 12. Anand K et al. *Clin Lung Cancer*. 2020;21(5):437-442. 13. Seidman AD et al. *Popul Health Manag*. 2017;20(4):252-254.